Amgen Acquires Otezla for $13.4 Billion
socalTECH
AUGUST 26, 2019
Thousand Oaks-based Amgen announced this morning that it is acquiring Otezla , the anti-inflammatory drug used to treat psoriasis and psoriatic arthritis, which is currently owned by Celgene Corporation , in a deal worth $13.4 Amgen said the acquisition will accelerate both its near- and long-term revenue growth. Otezla had $1.6
Let's personalize your content